Moderator: Dr. Mohammed Ezzi

Sponsor: RAND

Presenters:

1. Prof Ignace De Hingh, MD, PhD, Catharina Cancer Institute, Eindhoven, The Netherlands
2. Umberto Carletti, Clinical perfusionist, Product Manager,  RAND
3. Dr. Abdi Hakin Mohammed, Surgical Oncologist, and Consultant Laparoscopic Surgeon, Mombasa.

Peritoneal metastases (PM) affect hundreds of thousands of patients a year globally. The patients have a very poor prognosis, without adequate treatment. PM is not a systemic but a regional disease, initially regarded as untreatable, resistant to systemic chemotherapy, and refractory to surgery. Accumulating evidence suggests that PM can be treated by radical regional combination therapy. Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal perfusion (HIPEC) is associated with significantly improved recurrence-free and overall survival in ovarian and Pseudomyxoma peritonei (PMP low-grade rare clinical condition) patients, without increasing toxicity. CRS-HIPEC program can be safely implemented in high-volume dedicated centers, though currently, there is an unmet need for this technology since there is no center in Kenya offering the services.  Rand Company in Italy is producing systems for HIPEC, which ideally should be effective, easy to use with automatic functions, traceable, safe, controlled, and supported by clinical experts. The cost of installing the machine is on average 3.4-4 million Kenya shillings and is cost-effective since each procedure requires one kit. The machine is easy to use and any nurse can use the machine without perfusion skills. The company offers training to individuals using the machine in their respective countries.